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Abstract
Vessel size imaging was used to assess changes in
the average vessel size of Shionogi tumors throughout
the tumor growth cycle. Changes in R2 and R2* relaxiv-
ities caused by the injection of a superparamagnetic
contrast agent (ferumoxtran-10) were measured using
a 2.35-T animal magnetic resonance imaging system,
and average vessel size index (VSI) was calculated for
each stage of tumor progression: growth, regression,
and relapse. Statistical analysis using Spearman rank
correlation test showed no dependence between ves-
sel size and tumor volume at any stage of the tumor
growth cycle. Paired Student’s t test was used to as-
sess the statistical significance of the differences in
average vessel size for the three stages of the tumor
growth cycle. The average VSI for regressing tumors
(15.1 ± 6.6 Mm) was significantly lower than that for
growing tumors (35.2 ± 25.5 Mm; P < .01). Relapsing
tumors also had an average VSI (45.4 ± 41.8 Mm) higher
than that of regressing tumors, although the differ-
ence was not statistically significant (P = .067). This
study shows that VSI imaging is a viable method for
the noninvasive monitoring of angiogenesis during
the progression of a Shionogi tumor from androgen
dependence to androgen independence.
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Introduction
Among American men, prostate cancer is currently the
most common and second most deadly form of cancer
(after lung cancer) [1]. Early detection greatly increases
the efficacy of possible treatment regimens: surgery to re-
move the tumor or radiation therapy (either external ther-
apy or brachytherapy). Once the tumor has metastasized,
the likelihood of survival drops drastically, and the only
effective form of systemic therapy is androgen withdrawal
[2]. Prostate cancer is one of many solid tumors that are
hormone-dependent. Several studies in animal models of
hormone-dependent tumors suggest a strong correlation be-
tween hormonal status and tumor microenvironment, including
blood supply [3].
Tumor microenvironment is an essential factor in the biology
and physiology of solid tumors, and it contributes to diagnostic
features and therapeutic response. Particularly important is
tumor blood supply, as many physiological parameters, such
as tissue oxygenation, metabolism, pH, and nutrient supply,
directly or indirectly depend on it [4].
Not only does vasculature supply the tumor with nutrients
necessary for growth, but, more importantly, there are an
increasing number of studies showing that the very nature of
tumor microvessels is strongly linked to the formation of me-
tastases. Weidner et al. [5] found that, in prostate cancer,
microvessel density correlates with both Gleason score and
metastasis. Angiogenic tumor cells promote new capillaries,
which have a leaky basement membrane. This allows tumor
cells easier access to the bloodstream and thus increases the
likelihood of metastasis. Moreover, cells forming the new tumor
are more likely to be angiogenic.
Thus, the growth of tumor microvasculature appears to
be critical to primary tumor growth and is a key factor in the
formation of metastases and, as a result, is linked to survival
[6]. Vascular endothelial growth factor (VEGF) appears to be
the primary signal for tumor vascularization. It is expressed at
low levels in normal tissues and appears to be linked to tumor
growth and angiogenesis in prostate tumors. It is expressed at
high levels during tumor growth, but androgen ablation leads
to a decrease in VEGF expression by tumor cells, resulting in
apoptosis of endothelial and tumor cells, leading to normaliza-
tion of tumor vasculature. With relapse, though, VEGF produc-
tion is increased again [7].
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For this reason, it has been proposed that a combined
hormone and antiangiogenic regimen could potentially be
very effective at treating prostate cancer [5,7–9]. Normal-
izing the tumor vasculature through an anti-VEGF has the
added benefit that it will improve the delivery and effective-
ness of conventional cytotoxic and molecularly targeted
therapies [8].
Measuring microvasculature to monitor the effectiveness
of these novel therapies is not easy. Jain et al. [7] and
Borgstrom et al. [6] used dorsal skinfold chambers in mice,
and Weidner et al. [5] used biopsy tissues to assess the
tumor microvasculature. Both of these techniques are inva-
sive and allow only part of the tumor to be observed. Tropres
et al. [10] proposed a novel contrast-enhanced technique for
characterizing the tumor vasculature. By measuring the in-
crease in transverse relaxation rates DR2 and DR2* caused
by the injection of an ultrasmall superparamagnetic iron ox-
ide (USPIO) contrast agent, it is possible to measure a
weighted average of blood vessel radii, known as the vessel
size index (VSI) [10].
The work of Tropres et al. [10,11] focused on brain tumors
and made the assumption that the blood–brain barrier
remained intact and that the contrast agent did not leak into
tissues during scanning. In this study, we evaluated the
feasibility of using VSI techniques to measure long-term
changes in the blood supply of subcutaneous tumors and
to assess the correlation between angiogenesis and a tu-
mor’s hormonal status in the Shionogi model of prostate can-
cer. To our knowledge, this is the first application of the VSI
technique to investigate subcutaneous tumors in a longitu-
dinal study.
Materials and Methods
Animal Preparation
All animal experimental procedures were carried out in
compliance with the guidelines of the Canadian Council for
Animal Care and were approved by the institutional Animal
Care Committee. The Toronto subline of transplantable
SC-115 AD mouse mammary carcinoma [12] was used in all
experiments. SeventeenmaleDD/Smicewere inoculated sub-
cutaneously with approximately 5 106 Shionogi cells on their
lower back.
In preparation for imaging, the mice were anaesthetized
with 4% isoflurane in air and then maintained at 1.5%. The
mice were placed on their back on an imaging bed with
the tumor centered in the coil. Body temperature was main-
tained at 35jC to 37jC using a hot water heating pad and
wasmonitoredwith a rectal probe.Remote injection of 200 mmol
Fe/kg contrast agent (ferumoxtran-10; Advanced Magnetics,
Cambridge, MA), followed by an approximately 0.05-ml saline
flush, was accomplished using a 27-gauge 1/2-in.-long needle
inserted into the tail vein and attached to a 0.38-mm-inner-
diameter polyethylene tubing.
Of 17 mice used in this study, 2 were euthanized precas-
tration due to ulcerating tumors, 2 died from complications
from castration, and 1 died in the magnet during imaging for
the second regression time point. Of the 12 remaining mice,
only 6 had relapsed androgen-independent tumors 15 weeks
following inoculation. Two VSI measurements were attempted
at least 48 hours apart for each stage of tumor progression in
each mouse.
Magnetic Resonance Imaging (MRI) Experiments
All MRI experiments were performed on a 2.35-T, 40-cm-
bore magnet (Bruker, Ettlingen, Germany) equipped with an
SMIS (SMIS, Surrey, UK) console using a 2.5-cm-diameter
three-turn solenoid coil. Imaging was performed in the trans-
verse plane on a 2-mm-thick slice through the center of the
tumor using a 128  128 matrix and a field of view of 40 mm.
For DR2 measurements, a spin-echo sequence with a repe-
tition time (TR) of 2500 milliseconds and an echo time (TE) of
60milliseconds was used; forDR2* measurements, a gradient-
echo sequence with TR/TE = 2500/10 milliseconds was used.
Apparent diffusion coefficient (ADC) was measured using a
diffusion-weighted spin-echo sequence with TR/TE = 2500/
60 milliseconds and a gradient factor b of 1000 sec/mm2
(distance between diffusion-sensitizing gradients D = 35 mil-
liseconds; duration of each diffusion-sensitizing gradient y =
15milliseconds; amplitudeG = 45.5 mT/m). A multislice proton
density-weighted (TR/TE = 2500/10 milliseconds) sequence
was used for tumor volume measurements.
Blood Susceptibility Measurements
For susceptibility measurements, five mice were injected
with 200 mmol/kg contrast agent, as described previously.
After allowing the agent to perfuse for 10 minutes, blood was
drawn out of the heart. Blood from the mice was mixed to-
gether and with heparin to prevent clotting. A sample was
then taken for only on an Instrumentation Laboratory Micro
13 pH/Blood Gas analyzer for pO2, pCO2, and blood pHmea-
surements and for centrifugation for hematocrit.
The susceptibility of blood with contrast agent was mea-
sured using a nuclear magnetic resonance spectroscopy
method [10]. Two 1.1-mm-inner-diameter heparinized glass
tubes filled with distilled water were placed in a 1.5-ml plastic
vial perpendicular to each other. The drawn blood was placed
in the vial and then the vial was placed in the magnet, with one
of water-filled capillaries aligned parallel to the magnetic field
B0 and with the other perpendicular to it. Susceptibility was
calculated from the difference in the resonant frequencies of
water in the two capillaries [10]. The susceptibility of bloodwith-
out contrast agent was calculated from measured hematocrit
and oxygen saturation hemoglobin values using the formula
described by Tropres et al. [10]. The susceptibility of oxygen-
ated and deoxygenated red blood cells was assumed to be
0.33 ± 0.09  106 and 1.97 ± 0.09  107, respectively [13].
Data Processing and Analysis
All MRI data were processed offline with a software pack-
age developed in-house using MATLAB (The MathWorks,
Inc., Natick, MA).
Tumor VSI was calculated by measuring the total signal
from a region of interest (ROI) encompassing the entire
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tumor in the slice and using that to calculate the DR2,
DR2*, and ADC values of the tumor [10]. Tumor volumes
were calculated from multislice proton density-weighted
spin-echo images. The border of the tumor was outlined
manually on each of the images, and tumor volume was cal-
culated by taking the sum of the areas in each slice multi-
plied by slice thickness.
The animals were divided into three experimental groups
corresponding to the three stages of the tumor progression
cycle: growth, regression, and relapse. Spearman rank–
order correlation coefficient was used to test for any corre-
lation between VSI and tumor size. Paired Student’s t test
was used to assess for differences in VSI throughout the
tumor progression cycle. In addition, Kolmogorov-Smirnov
test was used to compare VSI distributions between the
three experimental groups.
Results
The increase in blood susceptibility caused by the contrast
agent Dv was measured to be 6.37 ± 0.15 ppm.
Statistical analysis of all tumors using Spearman rank
correlation test showed no dependence between vessel size
and tumor volume at any stage of the tumor growth cycle
(overall Spearman rank correlation coefficient rs = 0.386, P =
.003; Figure 1).
Only six tumors successfully progressed to an androgen-
independent state. Figure 2 shows axial cross-sections
through the center of a representative tumor acquired at
different stages of the tumor growth cycle. Calculated VSI
maps are shown in the bottom row. The average VSI val-
ues from an ROI encompassing the entire tumor were 44,
6, and 92 mm for the growing, regressing, and relapsing
stages, respectively.
The average VSI for each stage of tumor progression was
calculated using all measurements made on mice in that
stage and is shown in Table 1. In the 13 mice whose tumors
regressed, all but 2 saw their mean VSI decrease postcas-
tration; of the 6 mice that progressed to an androgen-
independent state, all but 1 experienced a subsequent
increase in tumor VSI (Figure 3). The longitudinal nature of
this study lends itself well to an analysis that takes into
consideration the dependent nature of measurements;
hence, paired Student’s t test was used to test the signifi-
cance of changes in tumor VSI. With a t statistic of 3.205 (P =
.0076), there is strong evidence to support a decrease in
vessel size postcastration in regressing tumors. The t statis-
tics for the difference between regressing and relapsing
tumors and between growing and relapsing tumors are
2.417 (P = .067) and 0.215 (P = .838), respectively.
Figure 4 shows a histogram of pixel VSI for all tumors
grouped into growing, regressing, and relapsing tumors.
Figure 1. VSI appears to be independent of tumor size. Overall Spearman
rank correlation coefficient rs = 0.386 (P = .003).
Figure 2. Axial cross-sections (top row) and VSI maps (bottom row) for a representative tumor at the growing (left column), regressing (middle column), and
relapsing (right column) stages of the tumor growth cycle. The average VSI value was 44 m for the growing tumor, 6 m for the regressing tumor, and 92 m for
the relapsing tumor.
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Regressing tumors had the largest number of small vessels
(VSI < 15 mm), whereas relapsing tumors had the largest
number of medium and large vessels (VSI > 30 mm). A
Kolmogorov-Smirnov test showed statistically significant dif-
ferences in VSI distributions between the three experimental
groups (Table 2).
Discussion
In this study, we examined changes in average vessel size
throughout the tumor growth cycle in the Shionogi model of
prostate cancer. Our results show that the VSI, which is a
measure of vessel radius, decreases significantly following
androgen ablation. The most likely reason for this decrease
is the reduction in the levels of VEGF following androgen
ablation. Shweiki et al. [14] showed that regressing tumor
vessels experience a significant reduction in their diameters
following VEGF neutralization with a blocking antibody.
Because androgen ablation results in a significant decrease
in VEGF levels in Shionogi tumors [7], this decrease will
subsequently trigger a concomitant decrease in vessel sizes.
Relapsing tumors showed increased vessel sizes, al-
though the difference in average VSI between regressing
and relapsing tumors failed to reach statistical significance
(P = .067). This increase in VSI represents the second wave
of angiogenesis, which was also reported by Jain et al. [7]. It
is interesting to note that vessels in relapsing androgen-
independent tumors were generally larger than vessels in the
original growing androgen-dependent tumors, as evidenced
by a comparison of vessel size distribution in all three groups
of tumors (Figure 4). This increased number of medium and
larger vessels (VSI > 30 mm) in relapsing tumors may be
related to slower tumor growth in this phase of the growth
cycle, which allows more significant vessels to form. This is
also supported by our previous study, which showed signifi-
cantly less heterogeneity in the perfusion pattern and higher
perfusion levels in androgen-independent versus androgen-
dependent Shionogi tumors [3]. The increased vessel sizes
in androgen-independent tumors may also reflect a more
aggressive phenotype of these tumors. It has been shown
that the size of vessels within a tumor varies with its ag-
gresiveness [15]. It is also known that androgen-independent
prostate tumors are more aggressive and are more likely to
metastasize. Thus, vessel size imaging may potentially
provide a noninvasive way of assessing tumor aggressive-
ness and propensity for metastasis, although more thorough
studies are required to test this hypothesis.
The vessel size imaging technique used in this study
relies on the contrast agent remaining in the vasculature
following injection for the duration of MRI measurements.
The permeability of tumor vessels is typically much higher
than that of vessels in normal tissues; thus, low-molecular-
weight agents typically leak out of the vasculature within
minutes of injection. The contrast agent used in this study is
Table 1. Average Tumor VSI Measurements in Each Stage of Shionogi
Tumor Progression.
Tumor Type VSI (mm) SD n Measurements (n Mice)
Growing 35.2 25.5 30 (17)
Regressing 15.1 6.56 22 (13)
Relapsing 45.4 41.8 11 (6)
Figure 3. Tumor VSI trends of six mice that progressed to an androgen-independent state. Error bars indicate the range of values for each average,
where available.
Figure 4. Histogram of pixel VSI for all tumors grouped into growing, re-
gressing, and relapsing tumors.
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part of a class of agents known as USPIO particles and has
been designed as a blood pool contrast agent. It consists of
an iron oxide core 4 to 6 nm in diameter coated in a dextran
shell (8–12 nm thick) to form a relatively inert particle. The
thick dextran layer reduces the reaction of the particle with
plasma proteins and reduces the rate at which particles are
eliminated by phagocytosis [16]. This yields a particle con-
trast agent with a relatively long half life of 4.5 hours in rat
blood plasma [10].
The validity of VSI measurements is limited by specific
assumptions in formulating the theory behind this technique.
In the lower limit, static dephasing and slow diffusion approxi-
mations limit measurements of VSI to values of > 7 mm [10].
The upper limit of validity for VSI measurements is based on
the need for sufficient averaging over the voxel for the
analytic spin-echo equation to be valid, thus setting an upper
limit of 50 mm based on an ROI encompassing the tumor on a
2-mm slice [17]. These limitations are likely the reason for the
differences between our results and those of Jain et al. [7],
who used dorsal skinfold chambers and optical microscopy
to assess changes in vessel diameter in Shionogi tumors
following androgen ablation. We measured the mean VSI for
growing tumors to be 35.2 mm, whereas Jain et al. reported a
mean vessel radius of 19.2 mm immediately before castra-
tion. In addition, Jain et al. saw the mean vessel radius drop
to 13.3 mm at 2 to 3 days postcastration and further drop to
4.7 mm at 2 weeks postcastration. Wemeasured the average
VSI for regressing tumors to be 15.1 mm, with the average
time of measurement at 6 days postcastration. Overestima-
tion of vessel sizes is likely due to the fact that the lower limit
of 7 mm used in calculating the mean VSI cuts off a large frac-
tion of the vessels and that the imaging technique leads to
an underestimation of DR2. This is consistent with previous
reports of overestimation of vessel diameters using the
vessel size imaging technique [10,18].
In addition to tumor VSI measurements, it is also possible
to construct a VSI map of the tumor by calculating the VSI for
each pixel (Figure 2). Although the statistical limits described
above are not satisfied by each pixel, the map gives valuable
information on the distribution of blood vessels [11] and can
be used to correlate VSI results with histology [19]. In the
current study, we did not carry out a quantitative correlation
between VSI maps and the corresponding histologic slides;
however, a qualitative comparison betweenVSImaps and ves-
sel distributions obtained with Hoechst dye 33342 (Sigma-
Aldrich, St. Louis, MO) staining (data not shown) demonstrated
generally good agreement. For larger tumors, where statistical
limits of VSI measurements are fulfilled, generating quantita-
tive VSI maps could provide a very useful way tomonitor the ef-
fectiveness of combined antiangiogenic therapies and could
possibly offer a noninvasive screening and grading technique
for prostate and other cancers.
Although a number of studies on the application of blood
pool contrast agents to investigate the tumor vasculature
have been reported before, vessel size imaging is a relatively
new technique [19–24]. A majority of these studies have
been carried out on brain tumors and have focused on
testing the limitations of this technique [11,25,26] and on
correlating MRI results with histology [11,19,20,22]. To our
knowledge, the current study is the first study where vessel
size imaging has been applied to examine longitudinal
changes in VSI within the same tumors. The noninvasive
character of this technology is particularly suitable for longi-
tudinal investigation; considering that solid tumors are typi-
cally heterogeneous, studying the same tumors over time will
more likely provide statistically significant results, which was
the case in our study.
Vessel size imaging seems ideal to study in vivo the
function and morphology of the tumor vasculature, which
plays a critical role in tumor growth; its propensity to metas-
tasize; and its potential response to chemotherapy and
radiotherapy [27]. There has been recent increased interest
in antiangiogenic antivascular cancer therapies. Because
many of these therapies do not result in a significant growth
delay in tumor xenografts [28], vessel size imaging can
provide a noninvasive way of testing the efficacy of such
therapies. Recently, Kiselev et al. [18] applied the vessel size
imaging technique in brain tumor patients. They used a low-
molecular-weight contrast agent (Gd-DTPA) rather than a
blood pool contrast agent used commonly in VSI measure-
ments. To avoid problems with the contrast agent leaking out
of the vasculature, a very fast imaging technique (echo
planar imaging) had to be used to generate DR2 and DR2*
maps during the first pass of the bolus of the contrast agent.
As a result of the required very high temporal resolution,
spatial resolution in MRI images had to be sacrificed. Nev-
ertheless, they were able to generate quantitative measures
of vessel sizes in the tumors and normal brain tissues,
demonstrating that this technique can be used to study
human tumors. Considering the great research effort in
developing new MRI contrast agents over the last decade,
large-molecular-weight blood pool contrast agents will likely
be approved for human use soon. This will allow application
of the vessel size imaging technique in humans.
Conclusion
Vessel size imaging has proven to be a viable method of
monitoring angiogenesis during the progression of a Shionogi
tumor from androgen dependence to androgen indepen-
dence. It appears to work well for subcutaneous tumors and
has proven capable of distinguishing differences in the vas-
culature between the different stages of tumor progression.
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